Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

This Phase III multi-center study of DTaP-IPV-Hib, with or without Hep B, used as a booster vaccine in healthy infants and toddlers will be conducted with two controlled, blind-observer trial arms in Germany and the Czech Republic and an open-label trial arm in Spain. Subjects in Germany and the Czech Republic will receive (at 11 to 15 months of age) a booster dose of the same DTaP-IPV-HB-Hib investigational vaccine or the Infanrix hexa control vaccine they received during the primary series in Study A3L39 concomitantly with a booster dose of Prevenar 13. All subjects in Spain received 2 doses of the DTaP-IPV-HB-Hib investigational vaccine and a dose of Pentavac (DTaP-IPV//Hib) in the primary series, and will receive (at 18 months of age) a booster dose of Pentavac concomitantly with a booster dose of Prevenar 13.

Next Previous
Search
Trial Profile

This Phase III multi-center study of DTaP-IPV-Hib, with or without Hep B, used as a booster vaccine in healthy infants and toddlers will be conducted with two controlled, blind-observer trial arms in Germany and the Czech Republic and an open-label trial arm in Spain. Subjects in Germany and the Czech Republic will receive (at 11 to 15 months of age) a booster dose of the same DTaP-IPV-HB-Hib investigational vaccine or the Infanrix hexa control vaccine they received during the primary series in Study A3L39 concomitantly with a booster dose of Prevenar 13. All subjects in Spain received 2 doses of the DTaP-IPV-HB-Hib investigational vaccine and a dose of Pentavac (DTaP-IPV//Hib) in the primary series, and will receive (at 18 months of age) a booster dose of Pentavac concomitantly with a booster dose of Prevenar 13.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); Hib-DTP-hepatitis B vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi Pasteur

    • Most Recent Events

    • 07 Nov 2018 Results from U1111-1122-2329 and U1111-1122-2362 studies published in the Pediatric Infectious Disease Journal
    • 14 May 2018 Results from U1111-1122-2329 and U1111-1122-2362 studies published in the Pediatric Infectious Disease Journal.
    • 12 Dec 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top